Alkermes plc ( ALKS) - Stock Earnings
ALKS Upcoming earnings
Estimated EPS and revenue columns are available to paid members.
| Date | EPS (actual / est.) | Revenue low (est.) | Revenue (actual / est.) | Revenue high (est.) |
|---|---|---|---|---|
| July 28, 2026, midnight | — / — | — | — / — | — |
ALKS Quarterly earnings
Analyst consensus estimates are available to paid members.
| Date | Earnings | Revenue |
|---|---|---|
| 2025Q3 | 82.8 million USD | 394.2 million USD |
| 2025Q4 | 49.3 million USD | 384.5 million USD |
| 2026Q1 | -66.5 million USD | 392.9 million USD |
| 2026Q3 Est. | — | — |
| 2026Q4 Est. | — | — |
ALKS Yearly earnings
Analyst consensus estimates are available to paid members.
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | 355.8 million USD | 1.7 billion USD |
| 2024 | 367.1 million USD | 1.6 billion USD |
| 2025 | 241.7 million USD | 1.5 billion USD |
| 2026 Est. | — | — |
ALKS
Price: $52.85
Earnings Per Share: 0.90 USD
P/E Ratio: 39.41
Exchange: NMS
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: Ireland
Volume: 283127
Ebitda: 39.2 millionMarket Capitalization: 9.2 billion